The Pharmacy partnership program with nursing homes and assisted living facilities has benefited patients most vulnerable to COVID-19 with the vaccine rollout. The American Health Care Association and National Center for Assisted Living claim, so far, things are going ok.
How sharing patient info improves care and streamlines provider processes
Under New Jersey's final-offer arbitration system, median arbitration award was 5.7 times median in-network price. Researchers say use of billed charges leads to high awards.
By using proactive care approaches for mental health, we have a tremendous opportunity to provide better care, reduce costs, and improve quality of life for millions.
Briana Contreras of MHE spoke with Josh Claman, CEO of Rimidi about the strong need for a permanent remote patient monitoring, or RPM, reimbursement reform, and how our health industry can come together to influence this change. The two also discussed the benefits of RPM technology for underserved, uninsured or Medicaid populations, and the benefits of RPM during and beyond the COVID-19 pandemic.
Many pharmaceutical manufacturers are raising prices this year, but at a lower overall rate than in the past couple of years, according to a new analysis.
Telehealth solutions are here to stay.
More oncologists are experiencing burnout due to the loss of face-to-face interactions with patients, according to a report from Cardinal Health Specialty Solutions.
Amphastar Pharmaceuticals’ generic version will offer stiff competition to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar.
For practitioners, there are real and unsettling questions as to what awaits in the future. Practitioners will find a new and evolving landscape is searching for liability insurance for 2021 and beyond.
In this final part of a three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about their focus on social determinants of health and the Covid-19 vaccine.
New research by shows how one of the major scientific breakthroughs of recent years might be used to eliminate HIV infection.
In this second of a three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization, MLR rates and investing in telehealth models for the better care of its members.
In this first of three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization among its members and the elimination of low-value care.
Our top five COVID-19-related articles from 2020.
Drug and diagnostic approvals and biosimilars news were popular with readers.
New study findings demonstrate patients with treatment-resistant hypertension rarely get tested for primary aldosteronism.
From telemedicine to addressing social determinants of health, these are the top five episodes of the Tuning Into the C-Suite podcast of 2020.
In this final part of a six-part series, most are neutral-to-negative on chance of meaningful change.
How health tech was used in 2020 and an outlook on how it will be used in 2021 and beyond.
In this fifth part of a six-part series, data said respondents split on the effect of the pandemic on value-based care
The top five non-COVID-19-related news articles published on Managed Healthcare Executive® in 2020.
In this fourth part of a six-part series, data shows the pandemic severely affected revenues, expenses.
In this third of a six-part series, respondents give administration poor marks.
The most popular article from the Managed Healthcare Executive® print publication was a pre-pandemic story about the top 6 challenges facing healthcare executives.
In this second of a six-part series, the biggest concern is short supply.
In this week's episode, MHE's Senior Editor Peter Wehrwein spoke with Sumit Dutta, Optum Rx chief medical officer. The two spoke about COVID-19 vaccines and how the pharmacy benefit market responded to the pandemic.
Respondents ranked the importance of healthcare issues.
The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.
With the number of PCPs declining, health plans can come in to support PCPs and play an active role in improving overall health literacy.
